[144] Amneal Pharmaceuticals, Inc. SEC Filing

Rhea-AI Filing Summary

Amneal Pharmaceuticals (AMRX) reported a Form 144 notice showing proposed sales by an affiliate. The filer intends to sell 175,000 Class A shares with an aggregate market value of $1,637,900, against approximately 314.08 million shares outstanding, with an approximate sale date of 08/20/2025 on NASDAQ. The filing records the shares were acquired as stock options on 05/07/2018 from Amneal Pharmaceuticals. The form also discloses prior sales in the past three months totaling 137,680 Class A shares for gross proceeds of $1,272,163 (sales on 08/12/2025 and 08/20/2025). The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.

Positive

• Required Rule 144 disclosure completed with acquisition date and nature (stock options) provided
• Recent sales fully reported showing transparency: 137,680 shares sold for $1,272,163 in the past three months
• Planned sale amount quantified: 175,000 shares with aggregate market value of $1,637,900

Negative

• Insider selling activity totaling 312,680 shares (past three months plus planned sale) could be viewed negatively by some investors
• No explanation of purpose for the sales is provided in the filing (standard for Form 144 but limits context)

Insights

Securities Analyst

TL;DR: Insider sale of 175,000 shares (~$1.64M) is material in size but small relative to total float.

The Form 144 shows a proposed sale of 175,000 Class A shares valued at $1.64 million, following recent disposals of 137,680 shares for $1.27 million. While the dollar amounts are meaningful on an absolute basis, the proposed sale represents roughly 0.056% of the reported 314.08 million outstanding shares, so the impact on capital structure is limited. The shares were acquired via stock options in 2018, indicating these are option realizations rather than new dilution. For investors, the filing documents liquidity actions by an insider or affiliate but does not, by itself, indicate operational issues.

Corporate Governance Expert

TL;DR: Routine insider liquidity event with proper Rule 144 disclosure; no governance red flags in the form.

The filing provides required disclosures under Rule 144: acquisition date (05/07/2018), nature of acquisition (stock options), and recent sales with gross proceeds. The seller attests to lack of undisclosed material adverse information and the form lists broker details. There is no indication of an undisclosed related-party transaction or an unexpected executive departure. As a governance matter, the disclosures are complete for this filing type and consistent with a permitted sale of previously granted equity.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
CLASS A	MERRILL LYNCH 157 CHURCH ST, FL 26 NEW HAVEN CT 06510	175000	1637900.00	314079309	08/20/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
CLASS A	05/07/2018	STOCK OPTIONS	AMNEAL PHARMACEUTICALS			175000	05/07/2018	STOCK OPTIONS

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
ANDREW BOYER 400 CROSSING BLVD BRIDGEWATER NJ 08807	CLASS A	08/12/2025	33436	302694.00
ANDREW BOYER 400 CROSSING BLVD BRIDGEWATER NJ 08807	CLASS A	08/20/2025	104244	969469.00

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Amneal's (AMRX) Form 144 disclose?

The Form 144 discloses a proposed sale of 175,000 Class A shares valued at $1,637,900, acquired as stock options on 05/07/2018, and recent sales of 137,680 shares for $1,272,163.

When is the planned sale date for the shares in the Form 144?

The filing lists an approximate sale date of 08/20/2025 and identifies NASDAQ as the exchange.

How large is the proposed sale relative to Amneal's outstanding shares?

The proposed 175,000 shares compare to 314,079,309 shares outstanding, representing about 0.056% of the outstanding shares.

How were the shares acquired that are being sold under this Form 144?

The securities were acquired through stock options on 05/07/2018 from Amneal Pharmaceuticals.

What prior sales are reported in the filing?

Two sales are listed in the past three months: 33,436 shares on 08/12/2025 for $302,694 and 104,244 shares on 08/20/2025 for $969,469.